Madrigal Pharma (MDGL) – Analyst Ratings
-
Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at Evercore ISI, 'well positioned to execute on the launch of Rezdiffra'
-
Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MDGL Stock Lookup